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Background: Pim (proviral insertion in murine lymphoma) kinases are a small family of constitutively active, highly
conservative serine/threonine oncogenic kinases and have 3 members: Pim1, Pim2, and Pim3. Pim kinases are also
implicated in the regulation of B- and T- cell responses to cytokines and hematopoietic growth factors. The roles of
Pim kinases in the regulation of primitive hematopoietic stem cells (HSCs) are largely unknown.
Methods: In the current study, Pim1−/−2−/−3−/− triple knockout (TKO) mice were used to determine the role of Pim
kinases in hematopoiesis. Peripheral blood hematological parameters were measured in Pim TKO mice and
age-matched wild-type (WT) controls. Primary, secondary, and competitive transplantations were performed to
assay the long-term repopulating HSCs in Pim TKO mice. In vivo BrdU incorporation assay and ex vivo Ki67 staining
and caspase 3 labeling were performed to evaluate the proliferation and apoptosis of HSCs in Pim TKO mice.
Results: Compared to age-matched WT controls, Pim TKO mice had lower peripheral blood platelet count and
exhibited erythrocyte hypochromic microcytosis. The bone marrow cells from Pim TKO mice demonstrated
decreased hematopoietic progenitor colony-forming ability. Importantly, Pim TKO bone marrow cells had
significantly impaired capacity in rescuing lethally irradiated mice and reconstituting hematopoiesis in primary,
secondary and competitive transplant models. In vivo BrdU incorporation in long-term HSCs was reduced in Pim
TKO mice. Finally, cultured HSCs from Pim TKO mice showed reduced proliferation evaluated by Ki67 staining and
higher rate of apoptosis via caspase 3 activation.
Conclusions: Pim kinases are not only essential in the hematopoietic lineage cell development, but also important
in HSC expansion, self-renewal, and long-term repopulation.
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Pim1, Pim2 and Pim3 belong to a small family of
serine/threonine protein kinases and are evolutionarily con-
served in multicellular organisms. Pim1 and Pim2 were ori-
ginally identified from cloning the retroviral integration
sites in murine Moloney Leukemia virus (MuLV)-induced
lymphomas [1,2]. Pim3 was identified through high
throughput retroviral tagging in tumors of c-Myc trans-
genic mice deficient for Pim1 and Pim2 [3]. Although Pim
kinase genes are located on different chromosomes, they
encode proteins with a high degree of sequence homology
[4,5]. Additionally, the functions and expression patterns of* Correspondence: kangy@musc.edu.
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reproduction in any medium, provided the orPim kinases overlap significantly with each other [4,6,7].
For example, Pim3 can compensate for the loss of Pim1
and Pim2 in MuLV-induced lymphomagenesis [3]. EμMyc-
EμPim2 double transgenic mice develop B cell lymphoid
tumors similar to those seen in EμMyc-EμPim1 double
transgenic mice [8,9]. Pim kinases are constitutively active
and play an important role in tumor cell cycle regulation
and in cancer cell survival [5].
Over the last two decades, several genetically modi-
fied mice were generated to facilitate the studies of the
functional roles of Pim kinases. These animal models
included Eμ-Pim1 transgenic mice [8], Pim1−/− single
knockout (KO) mice [10], Pim2−/− single KO mice
[11], and Pim1−/−2−/−3−/− triple KO (TKO) mice [4].
Pim1−/− and Pim2−/− single KO mice do not show anyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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functional redundancy and overlap of Pim kinases. Pim sin-
gle or triple KO mice are all viable and show subtle
hematological changes such as anemia, erythrocyte micro-
cytosis, reduced peripheral T- and B- cell numbers, and
impaired T- and B- cell responses to IL-2, IL-3 and IL-7
stimulation [4,10]. Grundler, et al. [12] recently found that
Pim1 was important in regulating the surface expression of
CXCR4 chemokine receptor in hematopoietic stem cells
(HSCs). Pim1 phosphorylates serine 339 of the intracellular
domain of CXCR4, a site critical for CXCR4 recycling [12].
However, very little is known about the effects of Pim
kinases on hematopoiesis and the roles of Pim kinases in
the expansion and proliferation of primitive HSCs.
We recently reported a quantitative real-time PCR-
based technique for determination of donor cell engraft-
ment in a competitive murine transplantation model
[13]. Our PCR method measures the Y chromosome spe-
cific gene, i.e., Zfy-1, and can be used for any strain of
mouse transplantation models. In the current study, we
performed serial transplant experiments and competitive
transplant experiments to analyze the hematopoietic
phenotypes of Pim TKO mice. We showed that Pim
TKO HSCs are deficient in self-renewal and long-term
repopulation. These defects are at least in part due to
reduced cell proliferation and increased cell apoptosis in
the most primitive HSC compartment in Pim TKO mice.
Results
Thrombocytopenia and erythrocyte hypochromic
microcytosis in Pim TKO mice
To determine the effects of Pim kinases on hematopoiesis,
we first measured peripheral blood white blood cells, red
blood cells, platelets and hemoglobin in 3 different age
groups of Pim TKO mice (i.e., 1–2 months old, 2–4 months
old and 6–7 months old). Sex- and age- matched wildtype
(WT) control mice were used for comparison. While the
total white blood cell counts were comparable between Pim
TKO mice and WT controls, the platelet count was signifi-
cantly reduced in Pim TKO mice (Figure 1A, p < 0.01).
Consistent with previous reports with Pim deficient mice
[4,10,11], Pim TKO mice exhibited erythrocyte hypochro-
mic microcytosis that was characterized by unchanged total
hemoglobin level with increased red blood cell count
(Figure 1B, 1st and 2nd panel). The erythrocyte hypochromic
microcytosis was further confirmed by measuring the mean
corpuscular volume (MCV) and the mean corpuscular
hemoglobin (MCH) of red blood cells, both of which were
significantly reduced in Pim TKO mice (Figure 1B, 3rd and
4th panel, p < 0.01). We then performed a detailed periph-
eral cell subset analysis that quantified the absolute number
of peripheral Gr-1+ granulocytes, CD3+ T cells, CD4+ cells,
CD8+ cells and B220+ B cells [14]. Compared to WT con-
trols, Pim TKO mice had significantly lower number ofCD3+ T cells, predominantly in the CD4+ T helper cell
population (Figure 1C, p < 0.01). Gr-1+ granulocytes were
also reduced in Pim TKO mice. These results suggested
that Pim TKO mice had impairment in multiple lineages of
hematopoietic cells.
Reduced hematopoietic stem/progenitor cell number and
colony-forming units in Pim TKO mice
Pim TKO mice were significantly smaller in size than het-
erozygous littermates [4]. Interestingly, when we measured
the spleen weight and adjusted it to the total body weight,
the Pim TKO mice still exhibited significant reduction in
the spleen-to-body weight ratio. The spleen-to-body weight
ratio was reduced by half in Pim TKO mice compared to
sex- and age- matched WT controls (Figure 2A, p < 0.01).
Additionally, Pim TKO mice had significantly lower num-
ber of total bone marrow cells (measured from 2 femurs
and 2 tibias of each mouse) (Figure 2B, p < 0.05). Total
number of splenocytes was also reduced in Pim TKO mice
in comparison to WT controls (Figure 2C, p < 0.01). These
data suggested a broadly diminished hematopoietic com-
partment in Pim TKO mice.
We next performed in vitro colony-forming unit (CFU)
assay to determine the frequency of hematopoietic stem/
progenitor cells (HSPCs) in the bone marrow (BM) of Pim
TKO mice. As shown in Figure 2D, CFUs-granulocyte/
macrophage (CFUs-GM), Burst-forming units-erythrocyte
(BFUs-E), and CFUs-granulocyte, erythrocyte, monocyte,
and megakaryocyte (CFUs-GEMM) were significantly
reduced in Pim TKO mice, demonstrating reduced clono-
genic activity of HSPCs in Pim TKO mice.
We also measured the percentage and absolute number
of Lin-Sca-1+c-Kit+ (LSK) cells in BM (Figure 2E). LSK
cells virtually account for all HSPCs in mice. We found
that the percentage of LSK cells in the BM of Pim TKO
mice was comparable to that in WT controls (Figure 2E).
However, since the total BM cell mass was reduced in Pim
TKO mice, the absolute number of LSK cells was signifi-
cantly lower in Pim TKO mice than in WT mice
(Figure 2F). To further characterize HSPC population in
Pim TKO mice, we measured long-term (LT)-HSCs
(CD34-CD135- LSK cells), short-term (ST)-HSCs (CD34-
CD135+ LSK cells), and multi-potential progenitor cells
(MPPs; CD34+CD135+ LSK cells) [15]. We found that the
percentages of LT-HSCs, ST-HSCs and MPPs were quite
similar between Pim TKO mice and WT controls
(Figure 2G), although one would expect that their absolute
numbers would be decreased in Pim TKO mice.
Reduced self-renewal and long-term repopulating
capacity of HSCs in Pim TKO mice
HSCs have the ability to self-renew and differentiate into
all lineages of hematopoietic cells. These functions are
best demonstrated using transplantation models in which
Figure 1 Reduced peripheral platelet counts and erythrocyte hypochromic microcytosis in Pim TKO mice. (A) Peripheral blood white
blood cell count and platelet count. (B) Peripheral blood hemoglobin, red blood cell count, MCV and MCH. Peripheral blood samples were collected
from 3 different age groups of Pim TKO mice and age-matched WT control mice. Peripheral hematological parameters were measured using Scil ABC
plus hematology analyzer (** p < 0.01). Group 1: 1–2 months old (n = 8 for Pim TKO mice); Group 2: 2–4 months old (n = 8 for Pim TKO mice); Group 3:
6–7 months old (n = 3 for Pim TKO mice). (C) Peripheral blood cell subset analysis. Peripheral blood was obtained from 3 months old Pim TKO mice and
age-matched WT controls, stained with various antibodies as described in the Materials and Methods, and analyzed by flow cytometry.
(*p < 0.05, **p < 0.01).
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and reconstitute the whole hematological system. We
transplanted lethally irradiated (11 Gy) FVB/J mice with
BM cells harvested from Pim TKO mice or sex- and age-
matched WT controls (5×105 cells/recipient mouse). As
showed in Figure 3A, the mice transplanted with WT BM
cells all survived after transplantation. In contrast, 75% of
the mice transplanted with BM cells from Pim TKO mice
died after transplantation. Additionally, those Pim TKO
BM transplant recipient mice that survived showed signifi-
cantly lower peripheral white blood cell counts at various
time-points post transplantation (Figure 3B). The platelet
count at 3 months post transplantation was also signifi-
cantly lower in Pim TKO BM transplant recipient micethan that in the mice transplanted with WT BM cells
(Figure 3C). The impaired hematological reconstitution
seen in Pim TKO primary transplant recipient mice was
not due to fewer number of LSK cells transplanted. All
mice received equal number of BM cells and the percen-
tages of LSK cells were similar between Pim TKO BM
grafts and WT BM grafts (Figure 2E).
To further define the role of Pim kinases on HSC self-
renewal and long-term repopulation, we performed second-
ary BM transplantation (Figure 4A-4B). BM cells were
harvested from primary BM transplanted recipient mice at
4 months post transplantation and injected into lethally
irradiated female FVB/J mice (1×107 cells/mouse). At 3
months post transplantation, the secondary transplant mice
Figure 2 Spleen weight, total BM cell number, and CFUs in Pim TKO mice. (A) Reduced spleen weight in Pim TKO mice. Spleens from Pim
TKO mice and WT controls were isolated and weighted. Data shown are the percentage of spleen weight to total body weight (n=5, **p < 0.01).
(B) Reduced total bone marrow cells in Pim TKO mice. Bone marrow cells from 2 femurs and 2 tibias were harvested from Pim TKO mice and
age-matched WT mice, depleted of RBCs, and counted (n=7, *p < 0.05). (C) Reduced total splenocytes in Pim TKO mice. Spleens from Pim TKO
mice and age-matched WT mice were harvested, depleted of RBCs and counted (n=5, **p < 0.01). (D) Reduced CFUs in Pim TKO mice. BM cells
were harvested from Pim TKO mice or WT controls and plated in MethocultW GF 3434 (1x105/dish in triplicate). The numbers of CFUs-GM, BFUs-E
and CFUs-GEMM were counted at day 7, day 9, and day 12, respectively (n=4, *p < 0.05, **p<0.01). (E) Comparable percentages of LSK cells in
Pim TKO mice. RBC-depleted BM cells were analyzed for LSK cell population. Data shown represent fold change over WT controls (n = 7). (F)
Reduced absolute number of BM LSK cells in Pim TKO mice. The absolute LSK cells were calculated by multiplying the total number of BM cells
(from 2 femurs and 2 tibias) with the percentage of LSK cells (n = 3, *p < 0.05 data representative of 3 independent experiments). (G) Unchanged
percentage of LT-HSCs, ST-HSCs, and MPPs in Pim TKO mice. Bone marrow cells were harvested, depleted of RBCs and enriched for Lin- cells
using lineage depletion kit. The enriched Lin- cells were then stained with CD34, CD135, Sca-1, and c-Kit antibodies as described in the Materials
and Methods. Data represent fold changes over WT control mice (n=5).
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eral white blood cell counts (Figure 4A). Donor cell engraft-
ment in BM was quantified at 4 months post
transplantation using a quantitative PCR-based method
measuring the sex-determining region Y (Zfy1) [13,16]. We
found that the male donor cells engraftment in secondary
Pim TKO transplant recipients was significantly lower than
that in controls (Figure 4B). Our data demonstrated that
the self-renewal potential and the long-term repopulating
capacity of HSCs were impaired in Pim TKO mice.
Competitive repopulating capacity of Pim TKO BM cells
was also examined. In this series of experiments, 5×105 BM
cells from male Pim TKO mice or male WT controls were
mixed with 2×105 of competitive WT female FVB/J BM
cells and transplanted into lethally irradiated female FVB/J
recipients. Male donor cell engraftment in peripheral blood
at 3 months post transplantation was estimated by quanti-
tative PCR. As shown in Figure 5A, mice transplanted withPim TKO BM cells had a lower percentage of donor-
derived male cells compared to control mice (p < 0.01).
These results indicated that Pim TKO BM cells were
less efficient and less competent in reconstituting the
hematopoietic system than WT BM cells. We also
determined donor cell engraftment in three main per-
ipheral blood cell subsets (i.e., Gr-1+ granulocytes,
T cells and B cells) in the competitive transplant re-
cipient mice. As shown in Figure 5B, the donor cell
engraftment was reduced in all these three cell subsets
in competitive transplant recipient mice receiving Pim
TKO BM cells, suggesting impairment in multi-
potential HSCs in Pim TKO mice.
Reduced HSC proliferation and increased apoptosis in
Pim TKO mice
To understand the mechanisms underlying the reduced cap-
acity of Pim TKO HSCs in reconstituting hematopoiesis, we
Figure 3 Reduced animal survival and delayed hematological recovery in primary transplant mice receiving BM cells from Pim TKO
mice. Lethally irradiated female FVB/J mice were injected via tail vein with BM cells obtained from male Pim TKO mice or male WT controls
(5 × 105 cells/recipient mouse (n=7/group)). Animal survival (A) was monitored daily. Peripheral blood white blood cell count (B) was measured at
1, 2, and 3 months post transplantation (*p < 0.05). Peripheral platelet count (C) was measured at 3 months post transplant (*p < 0.05).
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mice. We first measured in vivo BrdU incorporation in LT-
HSCs, ST-HSCs and MPPs of the mice. We observed sig-
nificantly lower number of BrdU positive cells in the Pim
TKO LT-HSC population (Figure 6A). The BrdU incorpor-
ation in ST-HSC and MPP compartments was not affected
in Pim TKO mice (Figure 6A). We next measured Ki67 la-
beling in cultured LSK cells in vitro. We sorted BM LSK
cells from Pim TKO mice or WT mice and cultured the
cells in StemSpan medium supplemented with growth fac-
tors for 48 hours. Consistent with our in vivo BrdU results,Figure 4 Delayed hematological recovery and reduced donor cell con
Pim TKO primary transplant recipients. BM cells were harvested from pr
injected into lethally irradiated female FVB recipients (1 × 107/mouse). (A) L
transplant recipient mice. Peripheral white blood cell count in the seconda
(n=6 for WT; n=3 for Pim TKO mice, *p < 0.05). (B) Reduced donor cell eng
The secondary transplant recipient mice were sacrificed at 4 months post t
cell engraftment (*p < 0.05).we found that the mean fluorescent intensity (MFI) of Ki-67
expression in Pim TKO LSK cells was reduced by 20% com-
pared to that in WT LSK cells (Figure 6B). These data sug-
gested that Pim TKO HSCs were less proliferative.
To determine the role of Pim kinases in regulating HSC
cell survival, we measured cell death and Caspase 3- activa-
tion in LSK cells ex vivo. Pim TKO LSK cells and WT LSK
cells were cultured in vitro with growth factors for 48
hours. Cell death was measured by live/dead fixable dye
and caspase 3- activation was determined by intracellular
caspase 3 antibody staining. Compared to WT LSK cells,tribution in secondary transplant mice receiving BM cells from
imary transplant recipients at 4 months post transplantation and
ower peripheral white blood cell counts in Pim TKO secondary
ry transplant recipient mice was measured at 3 months post transplant
raftment in the BM of Pim TKO secondary transplant recipient mice.
ransplant and BM cells were harvested and analyzed for male donor
Figure 5 Reduced repopulating capacity of Pim TKO BM cells in
competitive transplants. 5×105 total BM cells from male Pim TKO
mice or WT controls, along with 2×105 female competitor BM cells,
were transplanted into irradiated female recipients. (A) Reduced
engraftment capacity of Pim TKO BM cells. Male donor engraftment
in peripheral blood at 12 weeks post transplant was estimated
(**p < 0.01). (B) Reduced engraftment in all three main cell subsets
with Pim TKO BM cells. Gr-1+ granulocytes, CD3e+ T cells and B220+
B cells were sorted from pooled peripheral blood samples. Genomic
DNAs from each population were isolated and the male donor cell
contribution in these cell subsets was determined.
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(Figure 6C) and caspase 3- activation (Figure 6D).
Discussion
Hematopoiesis is regulated by many different molecular
pathways [17]. In the current study, we examined the role
of Pim kinases in regulating the primitive HSCs in mice.
We used serial transplant experiments, competitive trans-
plant assay, and in vivo and in vitro proliferation assays to
investigate the long-term repopulating HSCs in Pim TKO
mice. Our study provides direct evidence for an important
role of Pim kinases in hematopoiesis. Our findings are con-
sistent with and support previous observations reported by
others [4,10-12]. For instance, we found that Pim TKO
mice had reduced body size, displayed erythrocyte micro-
cytosis, and had reduced T cell numbers. We did not ob-
serve significant changes in the peripheral B- cell number.
This is also consistent with previous observation by
Mikkers, et al., who found that in young Pim TKO mice,
peripheral B- cell numbers were reduced whereas in older
animals, the B- cell number was unaltered [4]. Importantly,
our current study extended our observations beyond previ-
ous results. We demonstrated that: 1). Deletion of Pim
kinases affects multiple lineages of hematopoietic cells in-
cluding platelet counts (Figures 1). 2). Deletion of Pim
kinases affects the self-renewal and long-term repopulating
capacity of HSCs (Figures 3, 4, 5). 3). Deletion of Pim
kinases affects the proliferation of the most primitive HSCs
in vivo and in vitro (Figure 6). and 4). Deletion of Pim
kinases increases apoptotic cell death of HSCs (Figure 6).
Our study provides new insights into the roles of Pim
kinases in the regulation of HSCs.The reasons the effects of Pim kinases in HSCs were
not previously reported are: 1) Previous studies had been
focused on the effects of Pim kinases on T- and B- cells.
This seemed logical because overexpression of Pim1 kin-
ase induced clonal T cell lymphoma/leukemia [8]. 2) Pim-
deficient mice were generated on FVB/J background
[4,10,11]. FVB/J mice lack readily available surface mar-
kers to separate donor-derived cells from congenic
recipient-origin cells. This presents a technical challenge
in determining the long-term repopulating capacity and
self-renewal of HSCs in transplantation models. 3) The per-
centage of LSK cells in the BM of Pim TKO mice was com-
parable to that in WT controls, as we showed in Figure 2E.
In the absence of serial transplant experiments, this finding
may lead investigators to assume that HSC population is
unaltered in Pim-deficient mice. The PCR-based method
that we reported recently [13] allows us to reliably deter-
mine donor cell engraftment in our transplant experiments.
Several published studies suggested a potentially im-
portant role of Pim kinases in hematopoiesis and in
HSCs. For example, Pim1 is highly expressed in human
fetal hematopoietic tissues [18]. Additionally, Pim1 kin-
ase is a key target for HOXA9, a homeoprotein import-
ant in hematopoiesis [19]. Pim1 and Pim3 were found to
be important in maintaining the self-renewal of mouse
embryonic stem cells, and loss of Pim1 and Pim3 led to
cell differentiation [20]. Furthermore, overexpression of
Pim kinase protected hematopoietic cells from apoptosis
[21], and enhanced growth factor- independent survival
in myeloid cells [22,23]. Recent study by Grundler, et al.
[12] suggested that Pim1 kinase was critical in CXCR4
expression and HSC homing. Using transplant models,
our study provides direct evidence for an important role
of Pim kinases in hematopoiesis.
Pim kinases regulate diverse signal pathways in both
hematological and non-hematological malignant cells.
Pim kinases promote cell proliferation by regulating
enzymes that are important in cell cycle progression,
including Cdc25A [24,25] and p27kip1 [26]. Pim
kinases regulate cell survival by phosphorylating the
apoptotic protein BAD [27] and ASK1 [27]. Further-
more, Pim1 kinase regulates PRAS40 phosphorylation
and increases the activities of mammalian target of
rapamycin protein kinase [29]. Pim kinase was found
to be important in controlling energy metabolism and
cell growth [30]. Consistent with these observations in
cancer cells, our studies suggest that Pim kinases are
important in the regulation of cell proliferation and
survival in HSCs.
Our study has important implications. Pim kinases are
being investigated as a potential target in the drug develop-
ment for the treatment of cancer [31]. Several compounds
including pan- Pim inhibitors are currently under develop-
ment and have shown interesting preclinical activities in
Figure 6 Decreased proliferation and increased apoptosis of Pim TKO HSCs. (A) Decreased in vivo BrdU incorporation in LT-HSCs of Pim
TKO mice. Pim TKO mice or WT mice were injected with 2 doses of BrdU, and BM cells were harvested and labeled with antibodies. BrdU-positive cells
in LT-HSCs, ST-HSCs, and MPPs were analyzed (n = 6, **P <0.01). (B) Decreased in vitro Ki67 labeling in Pim TKO LSK cells. LSK cells were sorted from Pim
TKO mice or WT mice and cultured in StemSpan medium supplemented with TPO, SCF and Flt3 for 2 days. The cells were then stained with Ki67
antibody. Representative histogram of three independent experiments was shown (MFI: mean florescent intensity). (C) Increased cell death in Pim TKO
LSK cells. The cultured LSK cells were stained with Live/Dead dye and representative histogram of three independent experiments was shown. (D)
Increased caspase 3-activation in Pim TKO LSK cells. Cultured LSK cells were fixed and stained with caspase 3 antibody. Representative histogram of
three independent experiments was shown.
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of these inhibitors in human are very limited. Our current
studies suggest that it would be important to understand
and monitor the potential hematological side effects when
using Pim kinase inhibitors.Conclusions
We demonstrated that Pim kinases play a fundamental
role in HSC regulation. Our findings support the notion
that oncogenes are not only important in tumorigenesis,
but also involved in normal cell development. Identifying
these roles is an important step in developing safe and ef-
fective therapeutic agents for the treatment of cancers.Materials and methods
Antibodies and reagents
APC-conjugated anti- mouse CD117 antibody (c-Kit, 2B8),
APC-H7-conjuagted anti- mouse c-Kit antibody (2B8), PE-
conjugated anti- mouse Sca-1 antibody (E13-161.7), APC-
conjugated anti- mouse CD3e (145-2C11), PE-conjugated
anti mouse Gr-1 (RB6-8C5), PE-Cy7-conjugated Ki67
antibody (B56), FITC- labeled Caspase3 (C92-605)
antibody and FITC-BrdU Flow kit were purchased from
BD Pharmingen (San Diego, CA). FITC- conjugated anti-mouse B220 (RA3-6B2); PerCP-eFluor 710- labeled
anti- mouse CD135 (A2F10) and eFluor 450- conjugated
anti- mouse CD34 (RAM34) antibodies were purchased
from eBiosciences (San Diego, CA). Magnetic murine
lineage cell depletion kit was purchased from Miltenyi
Biotec (Auburn, CA). Aqua Live/dead fixable dye was pur-
chased from Invitrogen (Grand Island, NY).
Mice
Pim TKO mice
Pim1−/−2−/− and Pim2−/−3−/− double KO mice were
generated by Mikkers, et al. [4] and were a kind gift of
Drs Paul B. Rothman (Johns Hopkins University) and
Anton Berns (The Netherlands Cancer Institute).
Pim1−/−2−/−3−/− TKO mice were generated by systemat-
ically breeding the Pim1−/−2−/− and Pim2−/−3−/− double
KO mice and were on FVB/J background. Pim TKO
mice and WT controls were maintained in our specific
pathogen-free animal facility. The genotype of each
mouse used in the study was confirmed by PCR geno-
typing of tail DNA.
FVB/J mice
WT FVB/J transplant recipient mice were purchased
from the Jackson Laboratory. All our studies were
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South Carolina Institutional Animal Care and Use Com-
mittee approved- procedures.
Peripheral blood cell subset analysis
Whole blood hematological parameters including white
blood cell count, hemoglobin concentration, hematocrit,
platelet count, mean corpuscular volume (MCV), and
mean corpuscular hemoglobin (MCH) were measured
using Scil ABC plus hematology analyzer (scil animal
care company Ltd.) as per the manufacturer’s instruc-
tions. Peripheral blood cell subsets were quantified using
flow cytometry as described previously [25]. Briefly,
50 μl blood was stained with monoclonal antibodies
against various cell subsets [APC- CD3 (145-2C11),
APC-Cy7- CD4 (GK1.5), PE-Cy7-CD8 (53–6.7), FITC-
B220 (RA3-6B2), PE- Gr-1 (RB6-8C5)]. Equal volume
(50 μl) of Flow-Count fluorospheres (Beckman-Coulter)
was added before flow cytometric analysis. The absolute
cell counts were calculated using the following formula:
Absolute count (cells/μL blood) = (Total number of cells
counted/Total number of fluorospheres counted) ×
Flow-Count fluorosphere concentration.
Colony forming unit (CFU) assay
CFU assays were performed in complete M3434 methyl-
cellulose medium (Stem Cell Technologies) following
the manufacturer’s instructions. Briefly, BM cells from
Pim TKO mice or WT controls were resuspended in
complete M3434 medium and plated in 6-well plates at
1 × 105 cells/well. The assays were done in triplicate and
the number of CFUs-GM, BFUs-E and CFUs-GEMM
was counted at day 7, day 9 and day 12, respectively.
In vivo BrdU incorporation assay
In vivo BrdU incorporation was performed as described
previously with minor modifications [32,33]. Briefly, mice
were intraperitoneally injected with 2 doses (at 8 and 2
hours before sacrifice) of bromodeoxyuridine (5-bromo-2-
deoxyuridine [BrdU]; BD Biosciences) at 50 μg/gram of
body weight. BM cells were then isolated and enriched for
Lin- cell population using lineage cell depletion kit (Miltenyi
Biotec). At least 1.5×106 Lin- BM cells were labeled with
PE –conjugated anti- mouse Sca-1, APC- conjugated anti
mouse c-Kit, PerCP-eFluor- conjugated anti mouse CD135,
and eFluor 450- conjugated anti mouse CD34 antibodies,
followed by fixation and staining with FITC–conjugated
BrdU antibody (BrdU Flow Kit, BD Pharmingen), according
to the manufacturer’s protocol.
Hematopoietic stem cell transplantation (HCT)
For primary HCT, BM cells were isolated from male TKO
mice or age matched WT controls. The red blood cell
(RBC)- depleted BM cells were injected (cell doses wereindicated in the text) via tail-vein to lethally irradiated
(11Gy) female FVB/J recipient mice. Animal survival was
monitored daily. To determine hematological recovery, per-
ipheral blood was collected from transplant recipient mice
by retro-orbital sampling under anesthesia condition.
Whole blood cell counts were measured using a Scil ABC
plus hematology analyzer as per the manufacturer’s
instructions.
For secondary HCT, BM cells were obtained from pri-
mary transplanted recipient mice at 4 months post trans-
plantation, and 1×107 BM cells/recipient were injected into
lethally irradiated female FVB/J mice. Male donor cell en-
graftment was measured.
For competitive repopulation assay, 5×105 male BM
donor cells from Pim TKO mice or WT controls were
mixed with 2×105 female competitive BM cells from FVB/J
mice, and transplanted into lethally irradiated female FVB/J
mice.
Analysis of donor cell engraftment
Male donor cell engraftment in female transplant recipients
was determined as described [13,16]. Briefly, genomic DNA
was extracted from RBC- lysed peripheral blood cells or
BM cells using the DNeasy Kit (QIAGEN), and further
purified using Ethanol precipitation method. Twenty ng of
genomic DNA were mixed with SYBR Green PCR master
mix reagents (Bio-Rad) and real time PCR was performed.
Donor cell engraftment was estimated by percentage of
male DNA calculated from the standard curve by PCR for
sex-determining region Y (Zfy1) [16]. Bcl-2: 5’-AAGCTG
TCACAGAGGGGCTA and 5’-CAGGCTGGAAGGAGA
AGATG or Actin: 5’-TGTTACCAACTGGGACGACA and
5’- ACCTGGGTCATCTTTTCACG were used as refer-
ence genes.
Cell sorting for CD3e+ T cells, Gr-1+ granulocytes, and
B220+ B cells
Peripheral blood samples (150 μl/mouse) were collected from
each group (5 mice/group) at 4 months post competitive BM
transplant and pooled. After RBC depletion, the leukocytes
were stained with APC- conjugated anti mouse CD3e, PE –
conjugated anti mouse Gr-1 and FITC -conjugated anti
mouse B220 antibodies and subjected to cell sorting on
Mo-Flo sorter (DakoCytomation). Sorted CD3e+ T cells,
Gr-1+ granulocytes and B220+ B cells were processed for
genomic DNA isolation. Male donor cell engraftment in each
cell subset was determined by real time PCR analysis as
described above.
In vitro culture of LSK cells and cell proliferation and
apoptosis assay
RBC-depleted total BM cells obtained from Pim TKO
mice or WT control mice were first enriched for
Lin- cells by Lineage selection kit. Lin- cells were then
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on flow cytometry for LSK cells. LSK cells (6,000/well)
were cultured in StemSpan SFEM medium (StemCell
Technologies) supplemented with 100 ng/mL of murine
stem cell factor (SCF), murine Thrombopoietin (TPO),
and murine Flt3 (all from Invitrogen) for 2 days. Cells
were then stained with Aqua Live/dead fixable dye
(Invitrogen) followed by fixation and permeabilization
(BD Cytofix/Cytoperm kit) according to the manufac-
turer’s instructions. The fixed cells were then stained with
PE-Cy7-conjugated Ki-67 antibody and FITC-labeled cas-
pase 3 antibody.
Statistical analysis
The values were reported as Mean ± SEM of multiple
experiments or Mean ± SD from a representative experi-
ment. Differences were analyzed by Student’s t test. p < 0.05
was regarded as significant.
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